English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

CT: computed tomography HPS: hemophagocytic syndrome LEP: lupus erythematosus panniculitis PET: positron emission tomography SPTCL: subcutaneous panniculitis-like T-cell lymphoma INTRODUCTION Lupus erythematosus panniculitis (LEP) most commonly presents as multiple deep subcutaneous indurated nodules or erythematous plaques involving the face and proximal extremities. Lipoatrophy is another characteristic feature on resolution. Histopathologically, LEP shows lymphoplasmacytic lobular panniculitis, often with dermal mucin deposition, hyaline fat necrosis, and lymphoid follicles. There may be epidermal vacuolar change and a perivascular and periadnexal lymphocytic infiltrate with prominent plasma cells. Treatment options include antimalarials, systemic steroids, dapsone, or rituximab. LEPmay be limited to the subcutaneous fat; in such cases, it can be difficult to entirely exclude subcutaneous panniculitis-like T-cell lymphoma (SPTCL). Histopathologic findings of SPTCL showpleomorphic T cells in the subcutaneous adipose tissue in a pattern mimicking panniculitis. Since 2005, SPTCL has been restricted to ab pannicular infiltrates, usually CD8 and CD56 , and has an indolent outcome. These patients can be treated with systemic corticosteroids, bexarotene, interferon, or low-dose chemotherapy with a single agent such as methotrexate. In contrast, pannicular lymphomas with gd phenotype are usually CD8 and CD56 and may also involve the dermis or epidermis. These patients are generally treated with multiagent chemotherapy and stem cell transplantation, but the prognosis is poor. The histopathologic distinction of LEP and SPTCL can be challenging (Table I) because of significant overlap; other clues that can aid in differentiating LEP from SPTCL include the clinical presentation and

The coexistence of lupus erythematosus panniculitis and subcutaneous panniculitis-like T-cell lymphoma in the same patient